Exploring ‘Junk DNA’ to find undiscovered causes of cancer
Using a new way to measure genetic variation in key sections of noncoding DNA.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Using a new way to measure genetic variation in key sections of noncoding DNA.
Finding why immunotherapy doesn't work for some children with sarcoma tumours.
Looking into whether survivors of childhood cancer are at risk of severe infections.
An open label, single centre, single arm, prospective feasibility study evaluating the effectiveness of near-infrared fluorescence(NIRF)using indo-cyanine green(ICG)in intra-abdominal or intra-thoracic minimally invasive surgery(MIS)in paediatric oncology.
Novel biomarkers for PARP inhibitor trials for children with cancer
GOTHAM - A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in HAemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS) or relapsed/refractory cancers
Can we reduce or eliminate the sensory nerve damage caused by vincristine chemotherapy? Potential novel adjunct neuroprotective/analgesic therapies.
Development of a paediatric version of the Sarcoma Assessment Measure (SAM-Paeds): a specific tool for assessing quality of life in children with sarcoma
The use of proton beam therapy to improve outcomes in childhood abdominal tumours